Add BrightSurf on Google Email

Head and neck cancer: Markers to facilitate better treatment in the future

A study published in European Journal of Nuclear Medicine and Molecular Imaging identified specific genetic markers associated with high risk of head and neck cancer. The research used DNA sequencing, artificial intelligence, and positron emission tomography to analyze cellular characteristics of tumors. These markers can facilitate mo...

SourceMedical University of Vienna·JournalEuropean Journal of Nuclear Medicine and Molecular Imaging·DateOct 25, 2022

In fine print: Study sheds light on mechanisms driving 1,2-dichloropropane-induced cancer in the printing industry

A new study led by Tokyo University of Science researchers identifies altered gene expression and cell function changes that drive DNA damage and neoplasia in cholangiocytes exposed to 1,2-dichloropropane. The findings highlight the importance of macrophage involvement in carcinogenesis.

SourceTokyo University of Science·JournalScientific Reports·TypeExperimental study·DateJul 25, 2022

Polymersomes efficiently deliver siRNA to treat breast cancers in preclinical model

Researchers have developed biodegradable nanovesicles that efficiently encapsulate and deliver PARP1 siRNA to breast cancer tumors in mice, inhibiting oncogene expression and extending survival. The polymersomes, assembled from three biodegradable block copolymers, have strong potential for precision-targeted therapeutic carriers.

SourceUniversity of Alabama at Birmingham·JournalACS Applied Bio Materials·TypeExperimental study·DateMay 24, 2022

Epilepsy drug stops nervous system tumor growth in mice

Researchers discovered that neurons carrying a mutation in the Nf1 gene are hyperexcitable and suppressing this hyperactivity with lamotrigine stops tumor growth in mice. The study provides an explanation for why some people with NF1 lack optic gliomas or neurofibromas, highlighting the critical role of neurons in tumor biology.

SourceWashU Medicine·JournalNature Communications·TypeExperimental study·DateMay 19, 2022

Patient-derived micro-organospheres enable cutting-edge precision oncology

Researchers developed a droplet-based microfluidic technology to produce micro-organospheres from cancer patient biopsies within an hour. These miniature tumors retain the original microenvironment and can be used for testing many drug conditions, showing almost perfect correlation with actual clinical treatment outcomes.

SourceTerasaki Institute for Biomedical Innovation·JournalCell Stem Cell·TypeExperimental study·DateMay 5, 2022

Specific cancer driving protein plays important role in lung cancer development, Moffitt researchers say

Researchers at Moffitt Cancer Center have identified ΔNp63 as a protein that contributes to lung cancer development by regulating stem cells and crucial elements known as enhancers. The study found that mice deficient for ΔNp63 in the lung developed fewer lung tumors and had fewer stem cells compared to control mice.

SourceH. Lee Moffitt Cancer Center & Research Institute·JournalNature Communications·TypeExperimental study·DateFeb 11, 2022

Systematically examining the way spatial structure influences the evolution of cancer

Researchers developed a computational model to simulate alternative spatial structures and types of cell dispersal in human tumors, finding that diverse spatial structures cause tumors to evolve differently. The model predictions are consistent with clinical data for cancer types with matching structures.

SourceCity St George’s, University of London·JournalNature·TypeComputational simulation/modeling·DateJan 14, 2022

Asthma may reduce risk of brain tumors -- but how?

Researchers found that asthma causes immune cells to behave in a way that prevents brain tumor growth, suggesting a potential new therapeutic approach. The findings suggest reprogramming T cells to act like those in asthma patients could be a new treatment for brain tumors.

SourceWashU Medicine·JournalNature Communications·TypeExperimental study·DateDec 10, 2021

Early signs of efficacy of new targeted agents and immunotherapies reported for multiple cancers at ESMO Congress 2021

New targeted therapies are being developed to target genetic alterations in cancer cells, such as the ARID1A mutation found in 10-50% of solid tumours. Early clinical trials suggest that these agents may be effective in treating multiple cancers, including breast, ovarian, and gastric cancer.

SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·DateSep 24, 2021

'Junk DNA' affects inherited cancer risk

A new study found that genetic variations in non-coding regions of DNA can drive cancer development. Researchers analyzed over 6 million genetic variants and discovered correlations between specific SNPs and the expression of oncogenes and tumour suppressor genes.

SourceCancer Research UK·JournalBritish Journal of Cancer·DateDec 5, 2019

The Lancet Oncology: Rapid scale-up of HPV vaccine and screening could prevent up to 13 million cases of cervical cancer by 2050

A modelling study predicts that combining high uptake of HPV vaccine and high HPV-based cervical screening rates can prevent up to 13.4 million cases of cervical cancer within 50 years. Cervical cancer elimination is expected in most countries by the end of the century, with average rates falling to less than 4 cases per 100,000 women.

SourceThe Lancet·JournalThe Lancet Oncology·DateFeb 19, 2019

Caught in the act: Papillomaviruses promote non-melanoma skin cancer

Researchers at the German Cancer Research Center have found that papillomaviruses associated with UV light can promote the development of non-melanoma skin cancer. The viruses affect the stability of host cell DNA, leading to accumulation of UV-related damage. This link has been previously underinvestigated in human biopsies.

Common food additive promotes colon cancer in mice

A recent study published in Cancer Research found that emulsifiers in processed foods can alter the gut microbiota in mice, leading to increased tumor development and inflammation. The study suggests that dietary emulsifiers may be partially responsible for the increasing incidence of colorectal cancer worldwide.

SourceGeorgia State University·JournalCancer Research·DateNov 7, 2016